Literature DB >> 20080206

Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation.

Roland Hjerpe1, Fabienne Aillet, Fernando Lopitz-Otsoa, Valerie Lang, Mónica Torres-Ramos, Rosa Farrás, Ronald T Hay, Manuel S Rodríguez.   

Abstract

In normal cells p53 is maintained at low level through the action of the ubiquitin-proteasome system. As a consequence of p53 transcriptional activity, various regulators of this tumor suppressor are produced, forming a negative feedback loop tightly controlling p53 stability. One of the most prominent is the ubiquitin-ligase Mdm2. Here, we have used a transfer of signals strategy to study the p53 degradation process promoted by Mdm2 in the absence of p53 transcriptional activity. Our results show that in a p53 null background, transcriptionally silent p53-fusions require multiple N- and C-terminal signals to be optimally targeted to proteasomal degradation. As for WT p53, p53-fusions able to form tetramers are polyubiquitylated and optimally degraded by the proteasome. However, p53 molecules unable to oligomerize, show Mdm2-mediated polyubiquitylation deficiency but are still targeted to proteasome degradation in vitro and ex vivo. In the presence of Mdm2, nuclear shuttling of p53 monomeric fusions favours proteasome-dependent degradability but not its polyubiquitylation. In vitro, 26S proteasome fails to drive degradation of OD mutants in the presence of Mdm2, suggesting the contribution of additional cellular factors in this process. All together, our results indicate that Mdm2-mediated proteasome-dependent degradation of polyubiquitylation deficient p53 monomers is mechanistically possible, taking alternative pathways to better achieve their proteolysis. These results support the existence of additional levels to regulate p53 stability and activity acting on individual subunits of the functional tetramer. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080206     DOI: 10.1016/j.biocel.2010.01.010

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  9 in total

1.  SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder.

Authors:  Valentina Del Dotto; Farid Ullah; Ivano Di Meo; Pamela Magini; Mirjana Gusic; Alessandra Maresca; Leonardo Caporali; Flavia Palombo; Francesca Tagliavini; Evan Harris Baugh; Bertil Macao; Zsolt Szilagyi; Camille Peron; Margaret A Gustafson; Kamal Khan; Chiara La Morgia; Piero Barboni; Michele Carbonelli; Maria Lucia Valentino; Rocco Liguori; Vandana Shashi; Jennifer Sullivan; Shashi Nagaraj; Mays El-Dairi; Alessandro Iannaccone; Ioana Cutcutache; Enrico Bertini; Rosalba Carrozzo; Francesco Emma; Francesca Diomedi-Camassei; Claudia Zanna; Martin Armstrong; Matthew Page; Nicholas Stong; Sylvia Boesch; Robert Kopajtich; Saskia Wortmann; Wolfgang Sperl; Erica E Davis; William C Copeland; Marco Seri; Maria Falkenberg; Holger Prokisch; Nicholas Katsanis; Valeria Tiranti; Tommaso Pippucci; Valerio Carelli
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

2.  Analysis of defective protein ubiquitylation associated to adriamycin resistant cells.

Authors:  Valérie Lang; Fabienne Aillet; Wendy Xolalpa; Sonia Serna; Laurie Ceccato; Rosa G Lopez-Reyes; Maria Paz Lopez-Mato; Radosław Januchowski; Niels-Christian Reichardt; Manuel S Rodriguez
Journal:  Cell Cycle       Date:  2017-11-20       Impact factor: 4.534

Review 3.  p53-based cancer therapy.

Authors:  David P Lane; Chit Fang Cheok; Sonia Lain
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-12       Impact factor: 10.005

Review 4.  Mdm2 links genotoxic stress and metabolism to p53.

Authors:  Zhongfeng Wang; Baojie Li
Journal:  Protein Cell       Date:  2011-01-08       Impact factor: 14.870

5.  Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2.

Authors:  James R Davis; Mohanad Mossalam; Carol S Lim
Journal:  Mol Pharm       Date:  2013-03-01       Impact factor: 4.939

6.  Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity.

Authors:  Valérie Lang; Chiara Pallara; Amaia Zabala; Sofia Lobato-Gil; Fernando Lopitz-Otsoa; Rosa Farrás; Roland Hjerpe; Monica Torres-Ramos; Lorea Zabaleta; Christine Blattner; Ronald T Hay; Rosa Barrio; Arkaitz Carracedo; Juan Fernandez-Recio; Manuel S Rodríguez; Fabienne Aillet
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

Review 7.  p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept.

Authors:  Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2016-11-10       Impact factor: 5.923

8.  Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers.

Authors:  Ana Maria Low-Calle; Joshua H Choe; Chen Katz; Oleg Laptenko; David Tong; Jazmine-Saskya N Joseph-Chowdhury; Francesca Garofalo; Yan Zhu; Assaf Friedler; Carol Prives
Journal:  Genes Dev       Date:  2018-03-16       Impact factor: 11.361

Review 9.  p53 tetramerization: at the center of the dominant-negative effect of mutant p53.

Authors:  Jovanka Gencel-Augusto; Guillermina Lozano
Journal:  Genes Dev       Date:  2020-09-01       Impact factor: 11.361

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.